EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSDNOG00000010246
Gene Symbol: GRIN3A
4 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSDNOG00000012259
Gene Symbol: GRIN3B
2 Cross references
289 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSDNOG00000012147
Gene Symbol: GRIK1
4 Cross references
316 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSDNOG00000011886
Gene Symbol: GRIK2
2 Cross references
336 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSDNOG00000008042
Gene Symbol: GRIK3
2 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSDNOG00000030953
Gene Symbol: GRIK4
4 Cross references
263 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSDNOG00000038266
Gene Symbol: GRIK5
2 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSDNOG00000042578
Gene Symbol: GRM2
2 Cross references
281 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSDNOG00000007112
Gene Symbol: GRM3
4 Cross references
213 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSDNOG00000045454
Gene Symbol: GRM4
2 Cross references
264 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSDNOG00000008117
Gene Symbol: GRM5
2 Cross references
278 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1-Like

Ensembl ID : ENSDNOG00000047793
Gene Symbol: LOC101435093
3 Cross references
275 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).